Unequivocal Discrimination of Leucine and Isoleucine in De Novo Antibody Sequencing



November 12, 2020

Creative Biolabs recently has unprecedentedly achieved the precise identification of leucine and isoleucine by mass spectrometry, advancing breakthrough science on protein/antibody sequencing in research, diagnostic, and therapeutic industries. The discrimination of leucine and isoleucine has long been the key technical difficulties of de novo antibody sequencing. However, Creative Biolabs just took a massive leap forward into the new era of this field, with unchallenged ability to achieve 100% accuracy in antibody sequencing by precisely distinguishing between leucine and isoleucine, based on the proprietary Database Assisted Shotgun Sequencing (DASS) technology. https://www.creative-biolabs.com/next-generation-antibody-sequencing.html

Next-Generation Sequencing

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.